$900-Million Biopharmaceutical Park Planned for Shenzhen

Article

ePT--the Electronic Newsletter of Pharmaceutical Technology

The Shenzhen government is planning to build a new national biopharmaceutical park in the Shenzhen Grand Industrial Zone.

The city government in Shenzhen in southern China's Guangdong province is planning to build a 2.92-mile2 national biopharmaceutical park in the Shenzhen Grand Industrial Zone.

The center will be designed for biopharmaceutical research and development and will house businesses in the biomedical engineering, marine biotechnology, biopharmaceuticals, modern Traditional Chinese Medicines, and chemical drugs industries.

The RMB 7.2-billion (USD 900-million) project will be funded by government and nongovernmental organizations and is subject to approval by China's National Development and Reform Commission (NDRC). The base is expected to have annual revenues of RMB 100 billion (USD 12.5 million).

The NDRC also has approved two other biopharmaceutical bases in Changchun (Jilin province) and Shijiazhuang (Hebei province).

Recent Videos
Drug Digest: Strategic Partnerships
Michelle Bridenbaker from Unbiased Science discusses her thoughts on the key industry from 2024 and those she anticipates will impact the industry in 2025 and beyond.
Henny Zijlstra from Adragos Pharma chats about the trends affecting the outsourcing market, various strategies being employed by service providers, and the value of end-to-end services.
Related Content